Correct spelling for the English word "inh" is [ˈɪn], [ˈɪn], [ˈɪ_n] (IPA phonetic alphabet).
"INH" is an acronym for "Isoniazid," a potent antibiotic medication primarily used in the treatment and prevention of tuberculosis (TB) infections. Isoniazid is classified as a first-line antitubercular drug and is often prescribed as part of a combination therapy for TB control.
As a dictionary definition, "INH" can refer to the chemical compound isoniazid but is commonly used to denote the drug itself. Isoniazid is specifically designed to inhibit the growth and proliferation of Mycobacterium tuberculosis, the bacterium responsible for causing tuberculosis.
Isoniazid functions by interfering with the biosynthesis of mycolic acids, essential components of the bacterial cell wall, thus impairing bacterial growth and viability. In addition to its bactericidal properties against actively multiplying bacteria, INH also possesses weak bacteriostatic effects on dormant bacilli, making it effective against both replicating and non-replicating forms of TB.
It is usually administered orally and undergoes rapid absorption from the gastrointestinal tract, reaching therapeutic levels in the blood within an hour. Metabolism of INH occurs primarily in the liver, with acetylation being the main pathway. Genetic variations in acetylation capacity can result in varying drug response and toxicity among individuals.
Side effects associated with INH use may include hepatotoxicity (most frequently experienced), peripheral neuropathy, skin rash, GI disturbances, and hematological abnormalities. These adverse effects often necessitate close monitoring of liver function and the administration of pyridoxine (Vitamin B6) to mitigate neuropathy risks.
In conclusion, "INH" denotes the drug isoniazid, which is an essential medication utilized in the treatment and prevention of tuberculosis, showing its efficacy in inhibiting the